Amgen settles with Coherus over arthritis treatment
28-11-2019
jhvephoto / Shutterstock.com
California-based Amgen is barred from succeeding on its patent infringement claim against Coherus Biosciences, according to the US Court of Appeals for the Federal Circuit.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Amgen, Coherus BioSciences, US Court of Appeals for the Federal Circuit, Neulasta, USPTO, aBLA, FDA, biologics, estoppel
